Pacific Northwest Gl and Liver Update

Powered by: Liver Institute Northwest

A conference featuring cutting-edge clinical updates on the latest advances in the field

September 15 –16, 2023





Endoscopic Treatments for GERD: An Update on Transoral Incisionless Fundoplication

V. Raman Muthusamy, MD, MAS

Medical Director of Endoscopy, UCLA Health System Professor of Clinical Medicine David Geffen School of Medicine at UCLA

Disclosures

- Consultant, Research Support Boston Scientific
- Consultant, Research Support Medtronic
- Honoraria Recipient Ethicon/Torax Medical
- Consultant Interpace Diagnostics
- Consultant Medivators
- Stockholder Capsovision



- Why have prior endoscopic anti-reflux devices failed?
- The TIF procedure
- Indications, Patient work-up and Post-TIF care
- Evidence Summary
- Conclusions

Anatomy of the GEJ

Anatomy: Normal Valve Structures



Gray's Anatomy, 1997

Anatomical Causes for GERD



Anatomy: The Mechanics of Symptoms

Normal Anatomy Closed; no reflux **Functional Valve** Tight to the scope **Physiological Reflux**

(Infrequent & Mild)

VS

Abnormal Anatomy



Dysfunctional Valve



Symptomatic GERD (Frequent & Intense)



Endoluminal (Endoscopic) Treatment of GERD

Thermal methods

• Limit GER by collagen deposition around cardia

Suturing / stapling methods

• Alter angle of His or elongate/augment LES

Injection / bulking implant methods

Augment LES tone with mass effect

Endoscopic Approaches

- Thermal Therapy
 - Curon Stretta (Radiofrequency Energy)



- Bard Endocinch
- Wilson Cook ESD
- NDO Plicator
- "Bulking Agents"
 - Microvasive Enteryx
 - Medtronic Gatekeeper







Endoluminal Treatment: Approved devices

- FDA approval Dates
 - EndoCinch March 2000
 - Stretta system April 2000
 - Enteryx April 2003
 - NDO Plicator April 2003

My View of Endoscopic Antireflux Technologies: 2005-2018





- Why have prior endoscopic anti-reflux devices failed?
- The TIF procedure
- Indications, Patient work-up and Post-TIF care
- Evidence Summary
- Conclusions

Terminology

- Transoral incisionless fundoplication (TIF) is the name of the procedure
- EsophyX is the name of the device used to perform the TIF procedure





The EsophyX Device: How it works....



History of TIF

- 2005 Endoluminal Fundoplication
 - Gastrogastric plication; 10 fasteners; below z-line
- 2007 TIF 1.0 (also year of FDA approval)
 - Esophagogastric plication; 12 fasteners; 1 cm above z-line
- 2009 TIF 2.0
 - Up to 23 fasteners placed
 - More proximal placement of fasteners (1-3 cm above z-line)
 - > 20,000 procedures performed
 - EsophyX Z+ device introduced in November 2017

Evolution of TIF

TIF Procedure Evolution

خ TRANSORAL II	NCISIONL	ESS FUN		TION - TI	F		Transoral Incisionless Fundoplication 2.0	Transoral Incisionless Fundoplication 1.0	Endoluminal Fundoplication (ELF)
NORMAL	Baseline GERD	ELF	TIF 1.0	TIF 2.0	NISSEN	Commercial Introduction	2009	2007	2005
ANTI- BARRER HPZ Z-LINE		<u>.</u>	Commercial Cases to Date	22,051	673	186			
				•	% of Total Commercial Cases	96%	3%	1%	
			-TIF 1.5"	0		Plication Type	Esophago- gastric	Esophago- gastric	Gastro- gastric
	2			Fastener Placement	1-3cm Above Z-line; more length along greater curve of stomach	Above Z-line, 1cm	Below Z-line		
Arge 10 groups' Accessions July Editions. 1987 - 1737 10 groups Accessions July Editions. 1987 - 1737 10 groups Accessions Proc. 4 (1997 - 2009) 10 groups Accessions Proc. 4 (1997 - 2009) 10 groups Accessions Proc. 4 (1997 - 2009) 10 groups Accessions July Accession Biology (1992 - 143) 11 groups Accessions Proc. 4 (1997 - 2009) 11 groups Accessions July Accession Biology (1992 - 143) 11 groups Accession Biology (1992 - 143) 11 gr			Į		(F-1)	Average # of Fasteners	12 – 23	12	10
						Wrap	Yes	No	No

Impact of Device Modifications



Bazerbachi, Krishnan, Abu Dayyeh, Gastrointest Endosc 2019;90:370-83

TIF vs. Lap Fundoplication

EA.

Principles Of Antireflux Surgery	TIF [®] Procedure	Laparoscopic Fundoplication
Reduce hiatal hernia ≤ 2 cm		~
Repair hiatal hernia > 2 cm and close crura*	*	~
Elongate the intra-abdominal esophagus		A 100 A
Fundoplication		 Image: A second s
• Approximate and tighten the fundus around the distal esophagus		 Image: A second s
• Recreate the dynamics of the angle of His		~
Restore the distal high pressure zone	~	_

*As of June 22, 2017, EsophyX[®] device indication was expanded to include patients with hiatal hernias larger than 2cm when a laparoscopic hiatal hernia repair (HHR) reduces the hernia to 2 cm or less.

Endoscopic Imaging Pre- and Post-TIF



Bazerbachi, Krishnan, Abu Dayyeh, Gastrointest Endosc 2019;90:370-83

Schematic Video of TIF Procedure





- Why have prior endoscopic anti-reflux devices failed?
- The TIF procedure
- Indications, Patient work-up and Post-TIF care
- Evidence Summary
- Conclusions

Indications

- Age 18+
- Partial to incomplete response of daily GERD(> 1 yr) symptoms to PPI (> 6 mos)
- Hill Grade 1-2 flap valve
- Proven GERD by endoscopy, pH study or barium imaging
- Hiatal hernia
 2 cm
- Abnormal pH or endoscopy while on PPI

Contraindications

Patients with:

■ BMI ≥ 35



- Hiatal hernia > 2cm
- Hiatai nernia > 2cm
- Paraesophageal hernia
- Bleeding disorders
- Severe esophagitis
- Esophageal diverticulae
- Esophageal varices
- Esophageal infections or fungal disease
- Esophageal stenosis
- Strictures
- Obstructions
- Limited neck mobility
- Osteophytes of the spine
- Chronic cough
- Any kind of normal or abnormal esophageal anatomy which would not permit insertion of a device



Assessing the GEJ: Hill Grade



is patulous

Normal ridge of tissue approximates closely to the scope

Ridge is slightly less well defined and opens with respiration

Hiatus is wide open at all times and the sphincter is displaced axially

Axial and Transverse Hiatal Hernia Measurements



Diameter of this scope is ~1 cm, so HH is ~3 cm. If using a smaller scope, adjust calculation accordingly

Patient Selection



Bazerbachi, Krishnan, Abu Dayyeh, Gastrointest Endosc 2019;90:370-83

Procedure and Post-procedure management

- General anesthesia
- 45 min procedure time (range 30-60 min)
- 2 operators (one for scope; one for EsophyX device)
- Intraop paralysis/PEEP 5-10 cm H₂0 may aid in avoiding diaphragm during plication
- Prophylactic antibiotics as well as IVF and antiemetics typically given intra-procedurally
- Typically observed overnight

Upon Discharge....

Medications post-op prescriptions including:

- Analgesic for moderate to severe pain
- Antiemetic to control nausea and vomiting

- Anti-gas agent to relieve bloating and discomfort
- Laxative to control constipation and straining
- > PPIs short term, reduce risk of rebound



Post-procedure: Diet

- Day 0-3
 - Clear liquid diet
- Day 4-14
 - Blenderized/full liquid diet
- Week 3-4
 - Pureed foods
- Week 5-6
 - Medium soft foods

Food Guide

Yes 🌒 No	• • Post Procedure	Day 0-3	Day 4-14	Weeks 3-4	Weeks 5-6
	Water (non-carbonated)	•	•	•	•
	Milk, decaffeinated tea, caffeine free drinks	•	•	•	•
ds, Jar	Diet and decaffeinated drinks, diluted electrolyte drinks	•	•	•	•
inbi	Broth of any kind, strained soups (not tomato based)	•	•	•	•
v in	Diluted, light or diet apple or white grape juice	•	•	•	•
lov Cle	Non-acidic fruit or vegetable juice (without chunks)	•	•	•	•
	Liquid puddings and creams	•	•	•	•
	Sherbets, ice-creams, milk shakes (without chunks)	•	•	•	•
	Drinkable yogurt (no chunks)	0	•	•	•
spir	Protein-enriched commercially available shakes	0	•	•	•
liqu	Very liquid, potato-based mash	0	•	•	•
	Non-stringy vegetable mash	0	•	•	•
_	Baby food	0	•	•	•
	Cottage cheese	0	0	•	•
	Oatmeal	0	0	•	•
e, b	Well-cooked & pureed vegetables (mashed potatoes	0	0	•	•
for	Canned fruit (without skins)	0	0	•	•
t te	Bananas, melons, berries	0	0	•	•
Sof	Soft eggs, tofu	0	0	•	•
	Moist, mashed boneless fish	0	0	•	•
	Well-cooked lean ground food (e.g. turkey)	0	0	•	•
_	Small soft noodles	0	0	0	•
nue od	Non-sticky rice	0	0	0	•
foc	Cereals (softened in milk)	0	0	0	•
2 42	Soft cheeses	0	0	0	•

Post-procedure: Activity and F/u

Activity

- Week 1: Short distance walking encouraged, minimal physical activity, no lifting > 5lbs
- Week 2: Slow climbing stairs allowed, no intense exercise, no lifting > 5 lbs., sex allowed
- Week 3-6: No intense exercise, may lift up to 25lbs.
- Week 7: Resume normal activity
- Follow-up
 - 1-2 weeks post op
 - 3 months
 - If study, 6-9 months



Insurance Coverage

- Category 1 CPT code for TIF exists
 - 43210: TIF alone
 - 43281: TIF & Hernia repair
- Hybrid TIF (laparoscopic hernia reduction and endoscopic TIF) covered by all parties (Medicare and private insurance)
- Straight TIF (all endoscopic) covered by Medicare
- Authorization for straight TIF needed are with some private payors



- Why have prior endoscopic anti-reflux devices failed?
- The TIF procedure
- Indications, Patient work-up and Post-TIF care
- Evidence Summary
- Conclusions

TIF: Primary References Used



Gastroenterology 2020;159:1504-1525

SPECIAL ARTICLE

State of Evidence in Minimally Invasive Management of Gastroesophageal Reflux: Findings of a Scoping Review

Constant

Michael F. Vaezi,¹ Nicholas J. Shaheen,² and V. Raman Muthusamy³

¹Division of Gastroenterology, Hepatology, and Nutrition, Vanderbilt University Medical Center, Nashville, Tennessee, ²Division of Gastroenterology, Hepatology, and Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, and ³Vatche and Tamar Manoukian Division of Digestive Diseases, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California

Bazerbachi, Krishnan, Abu Dayyeh, Gastrointest Endosc 2019;90:370-83. Vaezi MF, Shaheen NJ, Muthusamy VR. Gastroenterology. 2020 Oct;159(4):1504-1525.

TIF: The Evidence Base

- 5 systematic reviews
- 5 Randomized trials
 - 2 c/t sham, 2 c/t PPI, 1 c/t lap Nissen fundoplication
- Multiple cohort studies
- >140 publications with at least 1600 unique patients
- Longest available f/u are 8 and 10 yrs

Effectiveness: Summary

- Improved heartburn, regurgitation and GERD-related QOL scores c/t sham procedures
- Acid reflux is reduced and even normalized in 40-80% of patients.
- Impact on LES pressures not as well studied
- Reduced need for PPI therapy at 5 yrs
 - 40-90% able to stop PPI use at various stages of f/u
- <u>TIF appears to be superior to PPI in eliminating or</u> reducing regurgitation or extra-esophageal symptoms

Systematic Reviews of TIF

- Meta-analysis of 32 TIF studies
 - 1232 patients in 26 studies with TIF 2.0 protocol
 - Procedural success rate (immediate) = 99%; AE = 2.0%
 - Significant improvement in GERD-HRQOL and pH scores
 - Hernia reduction achieved in 91%
 - PPI elimination in 88%
- SR and Network Meta-analysis of only RCTs of Lap Nissen or TIF w/ sham or PPI
 - 7 studies, 1128 patients
 - TIF with best improvement in HRQOL
 - Nissen better with objective parameters (LES pressure and acid exposure)

TIF 2.0 for Atypical GERD Symptoms

- 10 studies; 564 pts
- RSI 6 & 12 mo data
- Tech success, Adv.
 Events, satisfaction, PPI use collected
- RSI
 - 6 mo reduced by 15.72
 - 12 mo reduced by 14.73



Haseeb M et al, GIE, 97:3, 2023, 394-406

TIF 2.0 Data Summary

TIF 2.0 Procedure Delivers Consistent Results on Objective Outcome Measures



Completely Healed I Grade

Weighted incidence is 80% across 6 studies with follow-up > 6 mo in 122 patients; 84% across 2 studies follow-up > 36mo in 56 patients

Weighted incidence is 81% across 11 studies with follow-up > 6 mo in 568 patients

TIF & pH Reduction

pH Parameters Following TIF Procedure

Several published European and US studies demonstrate TIF procedure's positive effect on objective GERD pH measurements including DeMeester score, mean acid exposure time, and normalization of pH.

SUMMARY OF EFFECT ON OBJECTIVE MEASURES FOLLOWING THE PROCEDURE												
Study	Follow-up (months)	No. Patients	DeMeester score			Mean % time pH < 4 (*< 5.3)			Number of refluxes			pH
			Pre	Post	Р	Pre	Post	р	Pre	Post	Р	ization studies
Testoni 2015	24	23	22	19	0.4				66	43	0.5	
TIF Registry 24mo 2014	24	20	34.4	17.2	<0.001	8.9*	5.2*	<0.001*	119.7	71.4	0.001	55%
TEMPO 36mo 2017	30/36	40	36	26.9	≤0.0173	12.5*	8.9*	0.001*	168	105	<0.002	40%
Hakansson RCT 2015	6	15				7.8	3.6	0.003				69%
RESPECT 2015 ACG poster	6/12	129	33.6	23.9 / 24.7	<0.05							
Ihde 2019 C-TIF 2.0	9	29	35.3	10.9	<.01							95% 22 pts intact anatomy
*Please see individual studies for pH-metry Bravo vs. Digi trapper												

Adverse Events

- Serious adverse event (SAE) rate of 2.0-2.4% in the 2 largest metaanalyses
 - Nearly half (9/19) occurred with TIF 1.0 procedure
- This appears to be decreasing with time likely due to operator experience and device refinements
- Most commonly reported SAEs:
 - Perforation 0.9% (none in 5 RCT of TIF 2.0 technique)
 - Post-TIF bleeding 0.6%
 - Pneumothorax 0.5%

Systematic Reviews of TIF

- Long term (>= 3 yrs) TIF F/u
- 8 studies; 418 pts
- Mean f/u 5.3 yrs (3-10 yrs)



©()S=

Authors Sabrina Testoni^{*,1}, Cesare Hassan^{*,2}, Giorgia Mazzoleni³, Giulio Antonelli², Lorella Fanti⁴, Sandro Passaretti⁴, Loredana Correale³, Giulia Martina Cavestro⁴, Pier Alberto Testoni⁴

- The pooled proportion of **patient-reported satisfaction** before and after TIF was 12.3% [12.3–35.1] and 70.6% [51.2–84.6] respectively, corresponding to an odds ratio of 21.4 [3.27–140.5].
- Pooled rates of patients completely off PPIs and on occasional PPIs were 53.8%
 [42.0%-65.1%] and 75.8% [67.6–82.6]
- Pooled mean GERD-HRQL scores off PPI were 26.1 [21.5–30.7] and 5.9 [0.35.1– 11.4]
- Pooled rates of **heartburn and regurgitation** scores normalization were 73.0% [0.62–0.82] and 86% [75.0–91.0].

Very Long Term Durability

- 10 yr data: Testoni et al, Endoscopy International Open 2019; 07: E647–E654
 - 50 pts, 14 with 10 yr f/u
 - 91.7% w/ 10 yr f/u had stopped or halved anti-secretory use
- 8 yr data: Chimukangara et al, Surg Endosc. 2019 April ; 33(4): 1304–1309.
 - 2007-2014; N=57
 - Median f/u 97 months; 23 w/ long term f/u
 - 73% on daily anti-secretory use; 78% satisfied/neutral w/ GERD management
- 9 year data: Bell RCW et al, Ther Adv Gastroenterol 2021 1-11.
 - Single Center Prospective Registry 11/08-7/15; N =151; no hernia repair; f/u in 131
 - 64% with >50% reduction in GERD-HRQL at 4.92 median yr f/u
 - 22% on daily PPI among those w/ > 5 yr f/u; 22% revised to LNF

Concept of "C-TIF"

- Concomitant Surgical Hiatal Hernia Repair and TIF procedure
- For > 2 cm hiatal hernias
- Done in Operating Room
- 60 pts with > 2 cm hiatal hernia; 2018-2020
- 100% technical success
- Reflux Disease Questionnaire for frequency and severity improved significantly from (17.4 to 4.72; p < 0.01 and 16.7 to 4.56; p < 0.05, respectively) at 6 mos.
- GERD HRQL scores decreased in heartburn (23.26 to 7.37; p < 0.01) and regurgitation (14.26 to 0; p = 0.05).
- Reflux Symptom Index decreased after cTIF (17.7 to 8.1 post cTIF; p < 0.01).
- Mean DeMeester score decreased from 43.7 to 4.9 and acid exposure time decreased from 12.7% to 1.28% post cTIF (p = 0.06).

C-TIF vs. Laparoscopic Nissen Fundoplication

- Multicenter, retrospective; N=125 TIF and 70 LNF
- HH 2-5 cm in size; both groups got HH repair and fundoplication
- No difference in: stop/reduction in PPI use, dysphagia, esophagitis, disruption of wrap or HH recurrence
- TIF had shorter hospital stay, lower 30 d readmission, less bloating and lower early and serious AE

Length of hospital stay (days, median [IQR])	1 (1–1)	2 (1–2)	< 0.001
Readmission in 30 days [n (%)]	0	3 (4.3)	0.013
Adverse event [n (%)]			
 Early (<30 days) 	0	13 (18.6)	< 0.001
Early serious	0	3 (4.3)	< 0.001
Late (30 days to 1 year)	0	0	-
Late serious	0	0	-
 1-year mortality [n (%)] 	0	0	-
At 6 months [n (%)]			
Discontinued PPI use	76 (73.8)	40 (60.6)	0.07
Decreased PPI use	88 (85.4)	55 (83.3)	0.71
Start PPI use	0	0	-
 Bloating (new or worse than baseline) 	15 (13.8)	21 (30.0)	0.009



Jaruvongvanich VK et al, Endosc Int Open, 2023, E11-18

TIF vs. LNF





Endoscopic view of LNF

TIF

Additional Recent Data

- Cost Effectiveness
 - TIF cost effective compared to surgery or medical therapy (BID PPI) over 10 yrs & lifetime
 - Costs: TIF 2.0 (\$ 13,978.63) vs. \$ 17,658.47 for LNF and \$10,931.49 for PPI.
 - Compared to the PPI strategy, TIF 2.0 was cost-effective with an incremental cost of \$ 3,047 and incremental effectiveness of 0.29 QALYs, resulting in an ICER of \$ 10,423.17 /QALY gained.
 - TIF 2.0 dominated LNF
- Learning Curve
 - Proficiency achieved at 18-20 procedures; Maximum plication efficiency after 26 procedures
 - Overall procedure time about 39 min after 44 procedures
- TIF to Revise Prior LNF (N=20)
 - Esophagitis healed in 78% of patients & significantly improved GERD-HRQL and RSI scores.
 - Mean acid exposure time decreased from $12\% \pm 17.8$ to $0.8\% \pm 1.1$ (p = 0.028) with 9 patients with normalized pH post-TIF. McCarty TR et al, Endosc Int Open 2022; 10:E923-E932.

McCarty TR et al, Endosc Int Open 2022; 10:E923-E932. Dbouk M et al, Endosc Int Open 2021; 9:E1785-E1791. Ghosh G. et al, Surgical Endoscopy, 2023, Vol. 37, p. 3701–3709.

When to Use TIF?

Of the ~6.7M uncontrolled GERD sufferers, <30K elect surgery (due to invasiveness, high complication rates and side-effect profile)



Reference: Reavis KM, Perry KA. Expert Rev Med Devices. 2014 Jul;11(4), 341-50. Subramanian, CR and Triadafilopoulos G. Refractory gastroesophageal reflux disease. Gastroenterol. Rep. (2015) 3 (1): 4153.

My Thoughts on Why to Use TIF

- For patients who don't desire long-term medications (concerns about long-term side effects, drug interactions, compliance issues)
- GERD symptoms controlled by PPI but with persistent regurgitation or supra-esophageal symptoms
- Adequate fundoplication but not so tight as to lead to dysphagia/gas bloat (about 80% reduction in these symptoms c/w Nissen)
- Easy to revise
- Doesn't eliminate future surgical fundoplication as an option if needed or desired

Summary/Conclusions

- TIF appears to be a safe, effective and relatively durable technique anti-reflux procedure that improves symptoms, reduces PPI use and improves and often normalizes objective parameters of reflux (pH study)
- Careful patient selection and pre-procedure workup (hernia assessment) is essential to achieving clinical success
- The technique does not preclude subsequent fundoplication and may also be used after failed prior fundoplication

Robert G. Kardashian Center for Esophageal Health

